
    
      It is a multi-center , open-label, single arm study conducted in 2 parts. Dose-escalation
      part: Subjects will receive oral Clifutinib Besylate once on C0D1.After 3 days,they will
      receive Clifutinib Besylate once daily repeatedly until disease progression or unacceptable
      toxicity occurs, each cycle is defined as 28 days.

      Expansion part:Expansion cohort might be set to further investigate the safety and efficacy
      of Clifutinib Besylate at or lower MTD dose recommended by dose-escalation part.
    
  